Abstract
Our previous studies showed that the urokinase-type plasminogen activator receptor (uPAR) and the p16 tumor suppressor gene play a significant role in glioma invasion. We expected that downregulation of uPAR and overexpression of p16 using a bicistronic vector might cause a additive and cooperative effect in the suppression of glioma invasion and growth. The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had significantly lower levels of uPAR and higher levels of p16 than controls. Cell cycle analysis showed the bicistronic vector caused G0/G1 arrest of the cell cycle. In vitro glioblastoma cell growth and invasiveness were inhibited in Ad-uPAR/p16-infected cells compared with controls. Ad-uPAR/p16 suppressed the tumor growth of glioblastoma cell lines in an ex vivo intracerebral tumor model and an in vivo subcutaneous tumor model. Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aguirre Ghiso JA, Kovalski K, Ossowski L . 1999 J. Cell Biol. 147: 89–104
Andreasen PA, Kjoller L, Christensen L, Duffy MJ . 1997 Int. J. Cancer 72: 1–22
Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ . 1995 Cancer Res. 55: 1351–1354
Brooks PC, Clark RA, Cheresh DA . 1994 Science 264: 569–571
Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS . 1997 Oncogene 15: 2049–2057
Chintala SK, Sawaya R, Gokaslan ZL, Rao JS . 1996 Cancer Lett. 103: 201–208
Costello JF, Berger MS, Huang HS, Cavenee WK . 1996 Cancer Res. 56: 2405–2410
Dear AE, Medcalf RL . 1998 Eur. J. Biochem. 252: 185–193
Ellis V, Pyke C, Eriksen J, Solberg H, Dano K . 1992 Ann. NY Acad. Sci. 667: 13–31
Fahraeus R, Lane DP . 1999 EMBO J. 18: 2106–2118
Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, Kratzke RA . 1998 Oncogene 16: 3087–3095
Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP . 1996a Oncogene 13: 1615–1619
Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP . 1998 Neurology 51: 1250–1255
Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA,, Kyritsis AP . 1996b Oncogene 12: 103–110
Gladson CL, Cheresh DA . 1991 J. Clin. Invest. 88: 1924–1932
Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yacoub IZ . 1995 Am. J. Pathol. 146: 1150–1160
Go Y, Chintala SK, Mohanam S, Gokaslan Z, Venkaiah B, Bjerkvig R, Oka K, Nicolson GL, Sawaya R, Rao JS . 1997 Clin. Exp. Metastasis 15: 440–446
Go Y, Chintala SK, Oka K, Gokaslan Z, Sawaya R, Rao JS . 1996 Cancer Lett. 110: 225–231
Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW . 1997 J. Urol. 158: 636–641
Graham FL, Prevec L . 1991 Methods in Molecular Biology. Murray EJ (ed) The Humana Press: Clifton, NJ pp. 109–127
Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K . 1999 Cancer Res. 59: 3783–3789
Ichimura K, Schmidt EE, Goike HM, Collins VP . 1996 Oncogene 13: 1065–1072
Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B . 1994 Cancer Res. 54: 6353–6358
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH . 1994 Science 264: 436–440
Kyritsis AP . 1997 Practice Guidelines for Neurologic Therapy Lechtenberg R and Schutta HS (eds) New York: Marcel Dekker pp. 473–496
Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J . 1996 Oncogene 12: 63–67
Mignatti P, Rifkin DB . 1993 Physiol. Rev. 73: 161–195
Mohan PM, Chintala SK, Mohanam S, Gladson CL, Kim ES, Gokaslan ZL, Lakka SS, Roth JA, Fang B, Sawaya R, Kyritsis AP, Rao JS . 1999 Cancer Res. 59: 3369–3373
Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS . 1997 Oncogene 14: 1351–1359
Mohanam S, Chintala SK, Mohan PM, Sawaya R, Lagos GK, Gokaslan ZL, Kouraklis GP, Rao JS . 1998 Int. J. Oncol. 13: 1285–1290
Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS . 1993 Cancer Res. 53: 4143–4147
Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ . 1992 Ann. NY Acad. Sci. 667: 1–12
Naruse I, Heike Y, Hama S, Mori M, Saijo N . 1998 Anticancer Res. 18: 4275–4282
Nip J, Rabbani SA, Shibata HR, Brodt P . 1995 J. Clin. Invest. 95: 2096–2103
Pollanen J, Stephens RW, Vaheri A . 1991 Adv. Cancer Res. 57: 273–328
Reed JA, Loganzo FJ, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW . 1995 Cancer Res. 55: 2713–2718
Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M . 1997 Nature Med. 3: 313–319
Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS . 1996 Clin. Exp. Metastasis 14: 35–42
Schreiber M, Muller WJ, Singh G, Graham FL . 1999 Oncogene 18: 1663–1676
Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA . 1996 Cell 85: 27–37
Vassalli JD, Baccino D, Belin D . 1985 J. Cell Biol. 100: 86–92
Walker MD, Green SB, Byar DP, Alexander EJ, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MSJ, Mealey JJ, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KRJ, Wilson CB, Strike TA . 1980 N. Engl. J. Med. 303: 1323–1329
Wang J, Guo K, Wills KN, Walsh K . 1997 Cancer Res. 57: 351–354
Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA . 1996 Science 273: 1551–1555
Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA . 1994 J. Biol. Chem. 269: 32380–32388
Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tomonaga M, Nicolson GL, Rao JS . 1994a Cancer Res. 54: 3656–3661
Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, Nicolson GL, Rao JS . 1994b Cancer Res. 54: 5016–5020
Yu W, Kim J, Ossowski L . 1997 J. Cell Biol. 137: 767–777
Acknowledgements
Supported by NIH grants CA 75557 and CA 76350 (JS Rao) and CA80748 (J Fueyo and AP Kyritsis).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adachi, Y., Chandrasekar, N., Kin, Y. et al. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21, 87–95 (2002). https://doi.org/10.1038/sj.onc.1204999
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204999
Keywords
This article is cited by
-
Viruses, gene therapy and stem cells for the treatment of human glioma
Cancer Gene Therapy (2009)
-
Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas
Cancer Gene Therapy (2007)
-
Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior
Modern Pathology (2004)
-
Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism
Laboratory Investigation (2004)
-
Molecular mechanisms of glioma invasiveness: the role of proteases
Nature Reviews Cancer (2003)